Clinical trial · no report yet · Phase 2
PERSEVERE
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- NCT04849364 ↗
- Terminated
- Bryan Schneider, MD
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 46 | |
| Podcasts | 30 | |
| X threads | 24 | |
| Bluesky threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Breast Cancer; Triple Negative Breast Cancer
- Interventions
- Capecitabine; Talazoparib; Pembrolizumab; Inavolisib
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Arm 3 · Active comparator
- Enrollment
- 52
- Primary outcomes
- ARM 1c: Disease Free Survival (DFS) at 2 Years
- Sponsor
- Bryan Schneider, MD with Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer
- Start
- Aug 24, 2021
- Primary completion
- Oct 24, 2024
- Results posted
- Yes
- Registry record
- NCT04849364 · updated May 31, 2025